Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma
NCT06337318Phase 3Recruiting
- Sponsor
- National Cancer Institute
- Start
- Oct 2024
- Primary completion
- Mar 2032
- Countries
- 1
01
Overview
A Phase 3 trial of mosunetuzumab in follicular lymphoma (FL), sponsored by National Cancer Institute. Started Oct 2024; status: recruiting.
02
Drugs
mosunetuzumab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT06337318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06337318.